Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17501284 | 0.90 | ATR (1.00) | ATR | |
| SCHEMBL29397034 | 0.90 | ATR (1.00) | ATR | |
| SCHEMBL17501293 | 0.88 | ATR (1.00) | ATR | |
| SCHEMBL20081975 | 0.88 | ATR (1.00) | ATR | |
| SCHEMBL17501336 | 0.88 | ATR (1.00) | ATR | |
| SCHEMBL17501102 | 0.87 | ATR (0.78) | ATR | |
| SCHEMBL17527535 | 0.87 | ATR (1.00) | ATR | |
| SCHEMBL20081985 | 0.87 | ATR (0.90) | ATR | |
| SCHEMBL17501452 | 0.87 | ATR (1.00) | ATR | |
| SCHEMBL17501602 | 0.86 | ATR (1.00) | ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660301-B2 | Combination of ATR kinase inhibitors with PARP inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-05-30 | — | — | US | claimed |
| US-20210128723-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-05-06 | — | — | US | claimed |
| US-20210128572-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-05-06 | — | — | US | claimed |
| EP-3661560-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | claimed |
| WO-2019025440-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | claimed |
| WO-2018153972-A1 | COMBINATION OF ATR KINASE INHIBITORS AND ANTIANDROGENS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | claimed |
| WO-2018153969-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH RADIUM-223 SALT | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | claimed |
| WO-2018153971-A1 | COMBINATION OF ATR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | claimed |
| WO-2018153973-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | claimed |
| EP-3177619-B1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma AG (DE) | 2018-04-25 | — | — | EP | claimed |
| US-20170216304-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-03 | — | — | US | claimed |
| EP-3177619-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2017-06-14 | — | — | EP | claimed |
| US-9549932-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-24 | — | — | US | claimed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | claimed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | claimed |
| US-20230346927-A1 | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-02 | — | — | US | disclosed |
| US-11690911-B2 | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-06 | — | — | US | disclosed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020320-A1 | 2-(MORPHOLIN-4-YL)-L,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690911-B2 | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors | ATR, PDCD1, CHEK1 | ATR 1/4885 |
| US-20210128572-A1 | COMBINATION OF ATR KINASE INHIBITORS WITH PARP INHIBITORS | ATR, CHEK1, PARP1 | ATR 1/4885 |
| US-20210128723-A1 | COMBINATION OF ATR KINASE INHIBITORS AND PD-1/PD-L1 INHIBITORS | ATR, PDCD1, CHEK1 | ATR 1/4885 |
| US-20170216304-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ATR 3508/4885 |
| US-20230346927-A1 | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | ATR, PDCD1, CHEK1 | ATR 1/4885 |
| US-20160287604-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ATR 3508/4885 |
| US-11660301-B2 | Combination of ATR kinase inhibitors with PARP inhibitors | ATR, CHEK1, PARP1 | ATR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.